Application of CRISPR/Cas9 on multiple sclerosis target validation

Multiple Sclerosis is one of the serious diseases worldwide. Demyelination of neurons in the central nervous system is its fundamental cause. Genome engineering for various MS research has recently undergone a revolution since the establishment of the clustered regularly interspaced short palindromic repeats (CRISPR) technology. This includes research spanning from basic science to translational medicine and precise MS therapy. Researchers have been able to identify, visualise, modify, and annotate specific DNA and RNA regions in a variety of living organisms thanks to the prokaryote-derived genome editing systems CRISPR/CRISPR associated proteins (CRISPR/Cas).The identification, validation, and targeted delivery of the target are all significantly aided by the CRISPR/Cas systems. With considerable technical developments, CRISPR/Cas systems have proved to be very effective, accurate, and flexible when targeting the specified genetic site. Despite major advancements in this area, a number of challenges still need to be solved, including immunological reactions, off-target activities, and ethical concerns. The following article aims to provide an overview of the CRISPR clinical applications, including their benefits and drawbacks.